Summary
Alzheon aims to raise $40 million in an IPO of its common stock.
The firm is developing a treatment candidate for Alzheimer's Disease.
ALZH previously attempted to raise $70 million earlier in 2018. Its financial resources have dwindled since then.
Members of our private investing community, IPO Edge, get our best ideas and insights. Get started today >>

Quick Take
Alzheon (ALZH) intends to raise gross proceeds of $40 million of common stock from a U.S. IPO, according to an S-1 registration statement.
The clinical stage biopharmaceutical firm is focused on brain health, memory and aging therapeutics.
ALZH is seeking a significantly downsized IPO amount from its previous effort to raise $70 million.
I’ll provide a final opinion when we learn further details from the current process.

